



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	09/679,664
Filing Date	October 3, 2000
First Named Inventor	Stormann et al.
Group Art Unit	1647
Examiner Name	R. Landsman
Attorney Docket Number	1959-7394US (N-019 US)

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BL		Cotecchia et al., "Discrete Amino Acid Sequences of the $\alpha 1$ -Adrenergic Receptor Determine the Selectivity of Coupling to Phosphatidylinositol Hydrolysis", <u>J. Biol. Chem.</u> 267:1633-1639 (1992).	
		Ferguson et al., "Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures", <u>Ann. Rev. Biochem.</u> 57:285-320 (1988).	
		Liggett et al., "Sites in the Third Intracellular Loop of the $\alpha 2A$ -Adrenergic Receptor Confer Short Term Agonist-Promoted Desensitization", <u>J. Biol. Chem.</u> 267:4740-4746 (1992).	
		Okamoto et al., "Identification of a G <sub>i</sub> Activator Region of the $\beta 2$ -Adrenergic Receptor that is Autoregulated via Protein Kinase A-Dependent Phosphorylation", <u>Cell</u> 67:723-730 (1991).	
		Wang et al., "Identification of a Domain in the Angiotensin II Type 1 Receptor Determining G <sub>q</sub> Coupling by the Use of Receptor Chimeras", <u>J. Biol. Chem.</u> 270:16677-16682 (1995).	
		Wong et al., "Chimeric Muscarinic Cholinergic- $\beta$ -Adrenergic Receptors That Activate G <sub>i</sub> in Response to Muscarinic Agonists", <u>J. Biol. Chem.</u> 265:6219-6224 (1990).	

Examiner  
SignatureDate  
Considered

11.25.06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.